Galectin Therapeutics (GALT) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prothena (PRTA) has outperformed Galectin Therapeutics (GALT) over the past year, losing 16.8% versus a loss of 23.2%. Over five years, GALT leads with a +8.0% price change compared with -86.4% for PRTA. Prothena is the larger company by market cap ($442.0 million vs $367.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | PRTA |
|---|---|---|
| Share price | $3.64 | $8.61 |
| Market cap | $367.09M | $442.01M |
| 1-day change | +0.55% | +1.53% |
| YTD return | -12.50% | -9.84% |
| 1-year return | -23.21% | -16.81% |
| 5-year return | +8.01% | -86.43% |
| EPS (TTM) | $-0.43 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.13 | $11.80 |
| 52-week low | $2.03 | $7.73 |
| Distance from 52-week high | -48.95% | -27.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +202.20% | +148.55% |
| Average volume | 385.71K | 484.51K |
| Shares outstanding | 100.85M | 51.34M |
| Employees | 9 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
GALT vs PRTA FAQ
Which is bigger, Galectin Therapeutics or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $442.01M compared with $367.09M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, GALT or PRTA?
PRTA returned -16.81% over the past 12 months, compared with -23.21% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.